Trial Profile
An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2011
Price :
$35
*
At a glance
- Drugs Mycophenolate mofetil (Primary) ; Mycophenolate sodium
- Indications Renal transplant rejection
- Focus Adverse reactions
- Sponsors Roche
- 19 Nov 2007 Status changed from recruiting to discontinued.
- 20 Jan 2007 New trial record.